)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Australian Clinical Labs
Australian Clinical Labs (ACL) investor relations material
Australian Clinical Labs AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary28 Oct, 2026
Opening remarks and agenda
Quorum confirmed; meeting opened with an acknowledgment of Aboriginal and Torres Strait Islander custodians, followed by the Chair’s and CEO’s addresses, formal business and Q&A.
FY 2026 financial statements, Director’s report and Auditor’s report were tabled and taken as read.
Financial performance review
FY 2026 underlying EBIT was AUD 69.2 million; EPS rose 8.5% YoY and ROIC exceeded 25%.
Operational cash flow reached AUD 64 million in FY 2026.
Results faced industry funding cuts, inflationary costs, subdued market growth, Medicare fee reductions for B12 and urine testing, and lower respiratory and HBV testing.
Board and executive committee updates
Stephen Roche served as Board Chair and Greg Horan as Group CEO and Executive Director; Dr Amandeep Hansra and Christine Bartlett were independent non-executive directors standing for re-election.
Dr Hansra joined the Board on 1 July 2026 to fill a casual vacancy; Christine Bartlett stood for re-election after a three-year term and chairs the People and Culture Committee.
The Board unanimously recommended both directors’ re-election.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Australian Clinical Labs
- Margin and EBIT growth outpaced revenue, with strong cash returns and a stable outlook.ACL
H2 2026 - Underlying EBIT and NPAT rose despite lower revenue, with margin expansion and strong capital returns.ACLH1 2026
- Revenue and cash flow rose, directors re-elected, and a new share buyback was announced.ACLAGM 2025
- 6.4% revenue growth and 8.7% EBIT rise, with robust FY26 outlook and digital initiatives ahead.ACLH2 2025
- Revenue stable, non-COVID growth, 12c dividend, and key resolutions passed.ACLAGM 2024
- FY24 met guidance with strong cash flow, margin recovery, and a new share buyback program.ACLH2 2024
- Revenue up 9.5% to $369.2M, EBIT up 17%, FY25 guidance and 3.5 cps dividend reaffirmed.ACLH1 2025
Next Australian Clinical Labs earnings date
H1 202715 Feb, 2027
Australian Clinical Labs
Next Australian Clinical Labs earnings date
H1 202715 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Australian Clinical Labs Limited (ACL) is a private provider of pathology services in Australia, operating over 70 accredited laboratories. Annually, these laboratories conduct millions of test episodes for both clinicians and patients. ACL serves more than 90 public and private hospitals, including two of the largest private hospital groups in Australia, with a comprehensive range of services encompassing routine pathology tests, advanced molecular genetics testing, and pathology services for clinical trials, among others. The company is headquartered in Clayton, Victoria, and its shares are listed on the ASX.